Sangamo BioSciences (SGMO) Shares are Down -7.4%

Sangamo BioSciences (SGMO) has risen sharply, recording gains of 7.18% in the past 4 weeks. However, the stock has corrected -7.4% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.75% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.47% and the 50-Day Moving Average is 5.34%.The 200 Day SMA reached 23.26%


Sangamo BioSciences (NASDAQ:SGMO): After opening at $4.61, the stock dipped to an intraday low of $4.55 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $4.77 and the buying power remained strong till the end. The stock closed at $4.63 for the day, a gain of 1.31% for the day session. The total traded volume was 750,888. The stocks close on the previous trading day was $4.63.

Sangamo BioSciences (SGMO) : Currently there are 4 street experts covering Sangamo BioSciences (SGMO) stock. The most bullish and bearish price target for the stock is $30 and $8 respectively for the short term. The average price target of all the analysts comes to $15.25. The estimated standard deviation from the target is $10.18.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.